Document is current
Any future updates will be listed below
-
Authors
Bemmer, Emily R.
Boulton, Kelsie A.
Thomas, Emma E.
Larke, Ben
Lah, Suncica
Hickie, Ian B.
Guastella, Adam J. http://orcid.org/0000-0001-8178-4625
-
Funding
Funding for this research was provided by:
Australian Research Council Linkage Grant (LP110200562)
National Health and Medical Research Council (APP1061922)
Senior Principal Research Fellowship (1046899)
- License Information
-
More Information
Article History
Received: 14 July 2020
Accepted: 21 January 2021
First Online: 8 February 2021
Ethics approval and consent to participate
: Informed, written consent was provided by all participants. The study was approved by the University of Sydney Human Research Ethics Committee (Reference No. 2015/365).
: Informed consent for the anonymisation of data and publication of results was provided.
: I.H. is a Commissioner in Australia’s new National Mental Health Commission from 2012. He was a director of headspace: the national youth mental health foundation until January 2012. He was previously the chief executive officer (till 2003) and clinical adviser (till 2006) of beyondblue, an Australian National Depression Initiative. He is the Co-Director, Health and Policy at the Brain and Mind Centre that operates two early-intervention youth services under contract to headspace. He has led a range of community-based and pharmaceutical industry-supported depression awareness and education and training programs. He has led projects for health professionals and the community supported by governmental, community agency and pharmaceutical industry partners (Wyeth, Eli Lily, Servier, Pfizer, AstraZeneca) for the identification and management of depression and anxiety. He has received honoraria for presentations of his own work at educational seminars supported by a number of non-government organisations and the pharmaceutical industry (including Servier, Pfizer, AstraZeneca and Eli Lilly). He is a member of the Medical Advisory Panel for Medibank Private and also a Board Member of Psychosis Australia Trust. He leads an investigator-initiated study of the effects of agomelatine on circadian parameters (supported in part by Servier) and has participated in a multicentre clinical trial of the effects of agomelatine on sleep architecture in depression and a Servier-supported study of major depression and sleep disturbance in primary care settings. The other authors no competing interests and no conflicts to disclose.
